Boston Scientific (NYSE:BSX) Issues Q4 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its fourth quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.42-0.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.44. The company issued revenue guidance of ~$2.90 billion, compared to the consensus revenue estimate of $2.93 billion.Boston Scientific also updated its FY 2019
Pre-Market guidance to 1.55-1.58 EPS.

NYSE BSX opened at $45.47 on Tuesday. The company has a market capitalization of $63.66 billion, a PE ratio of 30.93, a price-to-earnings-growth ratio of 2.23 and a beta of 0.78. Boston Scientific has a 1-year low of $34.35 and a 1-year high of $46.62. The firm’s fifty day simple moving average is $44.60 and its 200-day simple moving average is $42.40. The company has a current ratio of 1.14, a quick ratio of 0.77 and a debt-to-equity ratio of 0.99.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.39 EPS for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.01. The business had revenue of $2.71 billion during the quarter, compared to analyst estimates of $2.68 billion. Boston Scientific had a net margin of 10.49% and a return on equity of 23.10%. The firm’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.35 earnings per share. As a group, analysts predict that Boston Scientific will post 1.57 EPS for the current year.

A number of equities analysts have issued reports on the stock. Needham & Company LLC cut shares of Boston Scientific from a strong-buy rating to a buy rating and set a $53.00 price objective on the stock. in a research note on Thursday, December 19th. Wells Fargo & Co raised their price objective on shares of Boston Scientific from $48.00 to $52.00 and gave the stock an overweight rating in a report on Monday, December 16th. Morgan Stanley lifted their price target on shares of Boston Scientific from $50.00 to $51.00 and gave the company an overweight rating in a research note on Tuesday, December 17th. Cowen lifted their price target on shares of Boston Scientific from $47.00 to $52.00 and gave the company an outperform rating in a research note on Monday, December 30th. Finally, Raymond James lowered their price objective on shares of Boston Scientific from $50.00 to $48.00 and set a strong-buy rating on the stock in a research note on Monday, October 14th. One investment analyst has rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $48.62.

In other Boston Scientific news, insider Williamson Scott bought 250,000 shares of the business’s stock in a transaction on Monday, November 4th. The stock was purchased at an average price of $0.12 per share, for a total transaction of $30,000.00. Also, SVP Desiree Ralls-Morrison sold 4,050 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $45.50, for a total transaction of $184,275.00. The disclosure for this sale can be found here. Insiders have sold 195,751 shares of company stock valued at $8,680,501 in the last 90 days. 0.66% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: What is the price-sales ratio?

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with's FREE daily email newsletter.

Leave a Reply